Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic

Summary Background Peanut allergy is a life‐threatening condition; there is currently no cure. While whole allergen extracts are used for specific immunotherapy for many allergies, they can cause severe reactions and even fatalities in peanut allergy. Objective To identify short, HLA‐degenerate CD4+...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental allergy Vol. 43; no. 6; pp. 684 - 697
Main Authors Prickett, S. R., Voskamp, A. L., Phan, T., Dacumos-Hill, A., Mannering, S. I., Rolland, J. M., O'Hehir, R. E.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.06.2013
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Background Peanut allergy is a life‐threatening condition; there is currently no cure. While whole allergen extracts are used for specific immunotherapy for many allergies, they can cause severe reactions and even fatalities in peanut allergy. Objective To identify short, HLA‐degenerate CD4+ T cell epitope‐based peptides of the major peanut allergen Ara h 1 that target allergen‐specific T cells without causing IgE‐mediated inflammatory cell activation, as candidates for safe peanut‐specific immunotherapy. Methods Ara h 1‐specific CD4+ T cell lines (TCL) were generated from peripheral blood mononuclear cells (PBMC) of peanut‐allergic subjects using CFSE‐based methodology. T cell epitopes were identified using CFSE and thymidine‐based proliferation assays. Epitope HLA‐restriction was investigated using blocking antibodies, HLA‐genotyping and epitope prediction algorithms. Functional peanut‐specific IgE reactivity to peptides was assessed by basophil activation assay. Results A total of 145 Ara h 1‐specific TCL were generated from 18 HLA‐diverse peanut‐allergic subjects. The TCL recognized 20‐mer peptides throughout Ara h 1. Nine 20‐mers containing the most frequently recognized epitopes were selected and their recognition confirmed in 18 additional peanut‐allergic subjects. Ten core epitopes were mapped within these 20‐mers. These were HLA‐DQ and/or HLA–DR restricted, with each presented on at least two different HLA‐molecules. Seven short (≤ 20 aa) non‐basophil‐reactive peptides encompassing all core epitopes were designed and validated in peanut‐allergic donor PBMC T cell assays. Conclusions and Clinical Relevance Short CD4+ T cell epitope‐based Ara h 1 peptides were identified as novel candidates for a safe, T cell targeted peanut‐specific immunotherapy for HLA‐diverse populations.
Bibliography:National Health and Medical Research Council of Australia
ArticleID:CEA12113
ark:/67375/WNG-97JJLB17-J
Ilhan Food Allergy Foundation
istex:50E3687EBCD480503E9F1F98861C2A5AF0E98A1D
Figure S1. Representative CFSE-based assay for detecting CD4+ T cell proliferation in PBMC.Figure S2. Representative HLA class II restriction specificity of T cell epitope recognition.Table S1. Subject demographics. Table S2. HLA genotyping for subjects used for T cell line generation. Table S3. Ara h 1 20-mer peptides. Table S4. Predicted HLA-DR binding motifs in selected Ara h 1 20-mers.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0954-7894
1365-2222
DOI:10.1111/cea.12113